<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">STAVUDINE (D4T)</span><br/>(sta'vu-deen)<br/><span class="topboxtradename">Zerit<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral</span>; <span class="classification">nucleoside reverse transcriptase inhibitor (nrti)</span><br/><b>Prototype: </b>Lamivudine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>15 mg, 20 mg, 30 mg, 40 mg capsules; 1 mg/mL solution</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic analog of thymidine (a major nucleoside in DNA) with antiviral action against HIV, the causative agent of AIDS.
         Phosphorylated to stavudine triphosphate by endogenous thymidine kinase. Appears to act by being incorporated into the growing
         DNA chains by viral transcriptase, thus terminating viral replication.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits the replication of HIV in human cells. Useful in patients with advanced disease, who are intolerant of other viral
         agents.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of adults with advanced HIV infection who are intolerant of other antiretroviral agents (zidovudine, didanosine,
         zalcitabine) or who have deteriorated on the other agents.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to stavudine; pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Previous hypersensitivity to zidovudine, didanosine, or zalcitabine; folic acid or B<sub>12</sub> deficiency; liver and renal insufficiency; peripheral neuropathy; history of pancreatitis.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Advanced HIV Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 60 kg, 30 mg q12h; <img src="../images/special/greaterorequal.gif"/><i>60 kg,</i> 40 mg q12h<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 30 kg, give 2 mg/kg/d in 2 divided doses; <img src="../images/special/greaterorequal.gif"/><i>30 kg,</i> same as adult<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 2550 mL/min: Reduce dose by 50% (also in patients with peripheral neuropathy)<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Adhere strictly to 12-h interval between doses.</li>
<li>Reconstitute powder by adding 202 mL of water to the container. Shake vigorously. Yields 200 mL of 1 mg/mL solution.</li>
<li>Store at room temperature, 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Peripheral neuropathy</span>, paresthesias. <span class="typehead">GI:</span>
<span class="speceff-common">Anorexia, nausea, vomiting, diarrhea,</span> cramping, pancreatitis, abdominal pain, elevated liver function tests, abdominal pain. <span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Headache,</span> chills/fever, <span class="speceff-common">myalgia</span>. <span class="typehead">Hematologic:</span> Anemia, neutropenia. <span class="typehead">Skin:</span>
<span class="speceff-common">Rash.</span>
<span class="typehead">Metabolic:</span> Lactic acidosis in pregnant women. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Didanosine</b> may increase risk of pancreatitis and hepatotoxicity; <b>probenecid</b> can decrease elimination. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; 82% reaches systemic circulation. <span class="typehead">Peak:</span> Effect 6 wk. <span class="typehead">Distribution:</span> Distributes into CSF; excreted in breast milk of animals. <span class="typehead">Metabolism:</span> Metabolized in liver; in addition to hepatic metabolism, some investigators suggest that degradation and salvage by other
      pyrimidine pathways may contribute to elimination; intracellularly, stavudine is phosphorylated by cellular enzymes to its
      active triphosphate form. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 11.6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for peripheral neuropathy and report numbness, tingling, or pain, which may indicate a need to interrupt stavudine.</li>
<li>Lab tests: Monitor liver enzymes, CBC with differential, PT and INR, and kidney function periodically.</li>
<li>Monitor for development of opportunistic infection.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take drug exactly as prescribed.</li>
<li>Report to physician any adverse drug effects that are bothersome.</li>
<li>Report symptoms of peripheral neuropathy to physician immediately.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>